Clinical Study to develop standard data of cognitive function screening tool, Processing Speed Test, on Japanese healthy volunteers

Not Applicable

• Conditions: Healthy people

• Registration Number: JPRN-UMIN000037340
• Lead Sponsor: Biogen Japan Ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-07-13
• Study Completion: 2019-08-29
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 270

Inclusion Criteria

Not provided

Exclusion Criteria

1.Subjects who have treated for or have history of any of following disease motor tic or vocal tic (including diagnosis of Tourette syndrome), head trauma with severe unconsciousness (more than 30 min), stroke (including ischemic and hemorrhagic stroke or transient ischemic attack (TIA)), neurological, developmental, medical, or conditional arterial disease including that in carotid artery, cerebral palsy, epilepsy, brain tumor, dementia (including mild cognitive disorder and Alzheimer's disease), chronic meningitis, multiple sclerosis, pernicious anemia, normal pressure hydrocephalus, HIV infection, Parkinson's disease, Huntington's disease, learning disability, attention deficit disorder, untreated hypertension (160/100 mmHg), severe cardiac disease, insulin-dependent diabetes mellitus, endocrine disorder, renal disease, glaucoma, or chronic obstructive pulmonary disease 2.Subjects with psychiatric disorder diagnosed by DSM-V criteria 3. Subjects with history of drug abuse and alcohol dependence syndrome 4. Subjects who are treated by currently prescribed psychotropic drugs for psychotic disorder, epilepsy, chronic sedative drug/hypnotic or narcotic analgesic (selective serotonin reuptake inhibitors (SSRI) and serotonin & norepinephrine reuptake inhibitors (SNRI) are permitted) 5. Subjects who are treated by any of following drugs which are expected to affect cognitive function Adderall, Ritalin(methylphenidate), TOPINA(topiramate), EXELON(rivastigmine tartrate), ARICEPT(donepezil hydrochloride), specific analgesic drug such as oxycodone

Study & Design

• Study Type: Others,meta-analysis etc
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Distribution of PST score

Secondary Outcome Measures

Name	Time	Method
1.Distribution of PST scores stratified by educational status 2.Distribution of PST scores stratified by age 3.Distribution of PST scores stratified by gender